INT70962

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.69
First Reported 1997
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 33
Total Number 40
Disease Relevance 27.32
Pain Relevance 2.14

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (SERPING1) extracellular region (SERPING1)
Anatomy Link Frequency
plasma 15
SERPING1 (Homo sapiens)
Pain Link Frequency Relevance Heat
bradykinin 371 98.04 Very High Very High Very High
headache 18 97.92 Very High Very High Very High
b2 receptor 58 97.56 Very High Very High Very High
cva 7 95.88 Very High Very High Very High
antagonist 106 94.88 High High
Pain 76 88.04 High High
corticosteroid 17 72.04 Quite High
Antihistamine 26 71.24 Quite High
nud 3 51.08 Quite High
Inflammation 49 42.48 Quite Low
Disease Link Frequency Relevance Heat
Hereditary Angioedema 1988 100.00 Very High Very High Very High
Pressure And Volume Under Development 1311 99.92 Very High Very High Very High
Disease 218 99.76 Very High Very High Very High
Laryngeal Edema 137 99.44 Very High Very High Very High
Repression 4 98.46 Very High Very High Very High
Recurrence 91 98.36 Very High Very High Very High
Targeted Disruption 38 98.32 Very High Very High Very High
Headache 18 97.92 Very High Very High Very High
Dizziness 8 97.40 Very High Very High Very High
Edema 357 97.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Even if effective androgen doses in HAE do not require a measurable increase of C1-INH in plasma, it is still possible that these drugs relay on C1-INH production and their efficacy is less when C1-INH catabolism is very rapid [38].
Positive_regulation (increase) of C1-INH in plasma
1) Confidence 0.69 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2925362 Disease Relevance 1.06 Pain Relevance 0
The half life of plasma- derived C1-INH in HAE indicates two infusions per week as the minimum to maintain protective prophylactic plasma levels [48].
Positive_regulation (derived) of C1-INH in plasma
2) Confidence 0.69 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2925362 Disease Relevance 0.69 Pain Relevance 0
We know that attenuated androgens can increase the plasma levels of C1-INH [37].
Positive_regulation (increase) of C1-INH in plasma
3) Confidence 0.69 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2925362 Disease Relevance 1.04 Pain Relevance 0
A phase I study of rhC1INH in which the drug was administered to 12 asymptomatic HAE patients at doses ranging from 6.25 to 100 U/kg [71] demonstrated a rapid increase in functional plasma C1INH activity and a corresponding fall in C4 activation, followed by a slower increase in C4 levels.
Positive_regulation (increase) of C1INH in plasma associated with hereditary angioedema
4) Confidence 0.67 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2921104 Disease Relevance 0.40 Pain Relevance 0
The best tolerated and most effective long-term prophylactic drugs are the synthetic anabolic androgens which increase C1INH plasma levels and decrease attacks of HAE [15].
Positive_regulation (increase) of C1INH in plasma associated with hereditary angioedema
5) Confidence 0.58 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2921104 Disease Relevance 0.79 Pain Relevance 0.04
Although C1-inhibitor deficiency has been known to be the underlying cause of HAE for more than 40 years, the actual mediator(s) of the vascular permeability characteristic of the disease remains the subject of continued investigation.
Positive_regulation (cause) of HAE associated with hereditary angioedema and disease
6) Confidence 0.55 Published 2008 Journal Clin Mol Allergy Section Body Doc Link PMC2374835 Disease Relevance 0.49 Pain Relevance 0.16
Complement system activation, in particular, would deplete C1-inhibitor because C1r and C1s are present in greater quantities than most of the other proteases and because complement activation in HAE tends to be extensive.
Positive_regulation (activation) of HAE associated with hereditary angioedema
7) Confidence 0.55 Published 2008 Journal Clin Mol Allergy Section Body Doc Link PMC2374835 Disease Relevance 0.15 Pain Relevance 0.07
Even if one assumes that AAE patients will not require a more intensive program because of the faster C1-INH catabolism and will not increase the risk of becoming resistant to plasma-derived C1-INH, this prophylactic infusion regimen seems justified only for those patients with two or more severe attacks per week, a condition that we did not find in any of our 42 AAE patients.
Positive_regulation (derived) of C1-INH in plasma associated with pressure and volume under development
8) Confidence 0.50 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2925362 Disease Relevance 0.68 Pain Relevance 0
Based on the efficacy of replacement therapy with plasma-derived C1-INH in reverting laryngeal edema in patients with HAE [35], the same approach has been used for AAE.
Positive_regulation (derived) of C1-INH in plasma associated with pressure and volume under development and laryngeal edema
9) Confidence 0.50 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2925362 Disease Relevance 1.55 Pain Relevance 0
Measurement of C1-INH and C4 antigen in such patients is the first step.
Positive_regulation (Measurement) of C1-INH
10) Confidence 0.50 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2925362 Disease Relevance 1.21 Pain Relevance 0
Two of these patients were completely, and one partially, non-responsive to plasma derived C1-INH.
Positive_regulation (derived) of C1-INH in plasma
11) Confidence 0.50 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2925362 Disease Relevance 0.71 Pain Relevance 0.08
Plasma-derived C1 inhibitor - pdC1INH
Positive_regulation (derived) of C1 inhibitor in Plasma
12) Confidence 0.50 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2921362 Disease Relevance 1.02 Pain Relevance 0.07
Plasma-derived C1-INH - PdC1INH
Positive_regulation (derived) of C1-INH in Plasma
13) Confidence 0.50 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2921362 Disease Relevance 0.06 Pain Relevance 0
Bork and Barnstedt (2001) compiled data from HAE patients in Germany who received C1-INH concentrate for laryngeal edema and compared the length of attacks with patients who had laryngeal edema in the past, but did not receive C1-INH concentrate.
Positive_regulation (received) of C1-INH associated with hereditary angioedema and laryngeal edema
14) Confidence 0.49 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 1.12 Pain Relevance 0.09
The group found that the patients treated with C1-INH concentrate for symptoms of laryngeal edema had an average duration of symptoms of 15.3 ± 9.3 hours which was significantly shorter than patients who did not receive C1-INH concentrate and had a mean duration of symptoms of 100.8 ± 26.2 hours.
Neg (not) Positive_regulation (receive) of C1-INH associated with laryngeal edema
15) Confidence 0.49 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 0.95 Pain Relevance 0.06
They enrolled only patients with frequent attacks for two different studies: one group of 12 patients received C1-INH regularly to prevent acute attacks, and the other group of 31 patients had C1-INH available at home “on demand” for the treatment of acute attacks.
Positive_regulation (received) of C1-INH
16) Confidence 0.49 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 0.26 Pain Relevance 0
They also noted that serum C4 concentrations remained elevated much longer than C1-INH levels – staying at peak levels at least 24 hours post C1-INH infusion.
Positive_regulation (elevated) of C1-INH
17) Confidence 0.49 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621399 Disease Relevance 0.83 Pain Relevance 0.06
In some European countries two human derived C1-INH concentrates have been used successfully.
Positive_regulation (derived) of C1-INH
18) Confidence 0.49 Published 2008 Journal Recent patents on inflammation & allergy drug discovery Section Abstract Doc Link 19076006 Disease Relevance 1.02 Pain Relevance 0.24
In our opinion, the best approach is to dispense pdC1-INH concentrate directly to the patients so it is constantly available at home for use on demand.
Positive_regulation (dispense) of C1-INH
19) Confidence 0.49 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2920238 Disease Relevance 0.21 Pain Relevance 0.06
The precise mechanism by which anabolic androgens increase C1INH levels has not be elucidated [17]; but the dose of anabolic androgen should not be based on the C1INH response.
Positive_regulation (increase) of C1INH
20) Confidence 0.48 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2921104 Disease Relevance 0.88 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox